Geron Announces Fast Track Designation Granted to Imetelstat for Relapsed/Refractory Myelofibrosis

MENLO PARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to imetelstat for the...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials